Condition: B-cell Non-Hodgkin Lymphoma · Diffuse Large B Cell Lymphoma · Follicular Lymphoma · Sponsor: Iksuda Therapeutics Ltd.
This first-in-human study will evaluate the recommended dose for further clinical development, safety, tolerability, antineoplastic activity, immunogenicity, pharmacokinetics and pharmacodynamics of IKS03, a CD19 targeting antibody-drug conjugate, in patients with advanced B cell non-Hodgkin lymphoma (NHL).
This description comes directly from the study's public registry record.
David Browning · 615-975-7776 · david.browning@iksuda.com
Always discuss trial participation with your own doctor first.
| University of Maryland Baltimore | Baltimore, Maryland, United States | Withdrawn |
| Westmead Hospital | Westmead, New South Wales, Australia | Recruiting |
| Royal Adelaide Hospital | Adelaide, South Australia, Australia | Recruiting |
| Royal Hobart Hospital | Hobart, Tasmania, Australia | Recruiting |
| Linear Clinical Research | Perth, Western Australia, Australia | Recruiting |
| Jewish General Hospital | Montreal, Quebec, Canada | Recruiting |
| La Fondazione e l'Istituto di Candiolo | Candiolo, Italy | Recruiting |
| Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale San Raffaele | Milan, Italy | Recruiting |
| Istituto Europeo Clinico Humanitas | Milan, Italy | Recruiting |
| Istituto Europeo di Oncologia | Milan, Italy | Recruiting |
| Institut Catala D'Oncologia | Badalona, Spain | Recruiting |
| Hospital Universitario Quironsalud Madrid | Madrid, Spain | Recruiting |
+ 1 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05365659